Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Dermato-Onco2024 | Tissue-based profiling to predict SLN positivity in high-risk melanoma

Julian Kӧtt, MD, University Medical Center Hamburg, Hamburg, Germany, discusses the prognostic value of tissue-based profiling to detect sentinel lymph node (SLN) positivity in patients with high-risk melanoma. Gene expression profiling (GEP) has shown that it can precede sentinel lymph node (SLN) biopsies and improve the prognosis for melanoma-specific survival rates. SLN tissue-based profiling could lead to the initiation of early adjuvant therapies in patients with high-risk melanoma. This interview took place at The European Congress on Dermato-Oncology 2024 in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.